８例健康志愿者静脉滴注先锋美他醇（ｃｅｆｍｅｔａｚｏｌｅ，ＣＭＺ）后观察其血药浓度及药效学的改变，按随机交叉试验设计分别用１ｇ，ｑ６ｈ及２ｇ，ｑ１２ｈ，用药２ｄ，药物浓度达稳态后，分别静脉取血，分离血清后测其血药浓度及血清杀菌活性。结论：推荐临床用ＣＭＺ１ｇ，ｑ６ｈ方式给药，２ｇ，ｑ１２ｈ峰值虽高但谷值低且时间长，血清杀菌活性低于１ｇ，ｑ６ｈ。另外报道了３０例呼吸道及其他部位感染患者，应用ＣＭＺ１ｇ，ｑ６ｈ或２ｇ，ｑ１２ｇ治疗，结果经统计学处理无显著性差异。 Eight healthy volunteers were given intravenous drip of cefmetazole (CMZ), and their plasma concentrations and pharmacodynamic changes were observed. Randomized crossover design was conducted with cefmetazole (1 mg, q6h, 2g, q12h, After steady state, respectively, venous blood, serum was measured after the serum concentration and serum bactericidal activity. Conclusion: It is recommended that CMZ1g and q6h should be given clinically. The peak value of 2g and q12h is high, but the trough value is low and the time is long. The serum bactericidal activity is less than 1g and q6h. Also reported in 30 cases of respiratory and other parts of patients infected with CMZ1g, q6h or 2g, q12g treatment, the results were statistically significant no significant difference.